2024
Systemic anti-cancer treatment and healthcare utilization at end of life: A SEER Medicare analysis.
Adelson K, Canavan M, Niu J, Zhao H, Nortje N, Xiang J, Giordano S, Cheng L. Systemic anti-cancer treatment and healthcare utilization at end of life: A SEER Medicare analysis. Journal Of Clinical Oncology 2024, 20: 276-276. DOI: 10.1200/op.2024.20.10_suppl.276.Peer-Reviewed Original ResearchEnd-of-lifeSystemic anticancer therapyDay of deathIntensive care unit useIntensive care unitHealthcare utilizationEmergency departmentCombined chemo-immunotherapyEnd-of-life chemotherapy useAssociated with healthcare utilizationImmunotherapy useChemo-immunotherapyIncreased healthcare useEnd of lifeAdverse quality of lifeAssociated with higher EDCare unitQuality of lifeSystemic anti-cancer treatmentHospice useDay hospiceHospice enrollmentSEER-Medicare databaseUse of chemotherapyHealthcare useSystemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors. JAMA Oncology 2024, 10: 887-895. PMID: 38753341, PMCID: PMC11099840, DOI: 10.1001/jamaoncol.2024.1129.Peer-Reviewed Original ResearchNational Quality ForumQuintile 5Quintile 1Improve end-of-life careEnd-of-life careCohort studyNationwide population-based cohort studyPopulation-based cohort studyEnd of lifeElectronic health record databaseHealth care practicesColorectal cancerPopulation of patientsCox proportional hazards modelsAmerican Society of Clinical OncologyQuality ForumCare practicesOverall survivalPayment incentivesProportional hazards modelHighest quintileMultivariate Cox proportional hazards modelQuintileFlatiron HealthHazard ratioSystemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis.
Adelson K, Cheng L, Huang Y, Niu J, Zhao H, Nortje N, Xiang J, Giordano S, Canavan M. Systemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis. Journal Of Clinical Oncology 2024, 42: 11092-11092. DOI: 10.1200/jco.2024.42.16_suppl.11092.Peer-Reviewed Original ResearchSystemic anticancer therapyCombined chemo-immunotherapyLiquid tumorsSolid tumorsDay of deathEmergency departmentRates of systemic therapySystemic anti-cancer therapySEER-Medicare databaseAnti-cancer therapyChemo-immunotherapyLT patientsSystemic therapyCI patientsSEER-MedicareST patientsIdentified patientsCost of drugsAssociated with higher costsEnd of lifeAnticancer therapyImmunotherapyChemotherapyPatientsTherapy
2021
Implementation of Inpatient Palliative Care Consultation Triggers and Its Impact on Healthcare Use in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Xiang J, Prsic E, Adelson K, Prebet T. Implementation of Inpatient Palliative Care Consultation Triggers and Its Impact on Healthcare Use in Patients with Relapsed/Refractory Acute Myeloid Leukemia. Blood 2021, 138: 3018. DOI: 10.1182/blood-2021-149300.Peer-Reviewed Original ResearchRefractory acute myeloid leukemiaAcute myeloid leukemiaPost-intervention groupLength of stayAdvanced acute myeloid leukemiaPalliative care consultHigh symptom burdenLines of therapyCare consultEnd of lifeDay of deathSame admissionCare escalationSymptom burdenHospice enrollmentHealthcare utilizationSymptom managementPrimary teamMyeloid leukemiaEastern Cooperative Oncology Group performance statusRelapsed/Refractory Acute Myeloid LeukemiaHigh-risk hematology patientsAdvance care planning documentationPalliative care remainsPalliative care use
2020
Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life.
Riaz F, Gan G, Li F, Davidoff AJ, Adelson KB, Presley CJ, Adamson BJ, Shaw P, Parikh RB, Mamtani R, Gross CP. Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life. JCO Oncology Practice 2020, 16: e1355-e1370. PMID: 32678688, PMCID: PMC8189605, DOI: 10.1200/op.20.00010.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsEnd of lifeUse of chemotherapySystemic cancer therapySystemic therapyCheckpoint inhibitorsColon cancerElectronic health record-derived databaseUse of ICIsFDA approvalCell lung cancerPatterns of careCare of patientsMicrosatellite stable colon cancerMSS colon cancerPearson's chi-square testDrug Administration approvalPatient-level dataCancer therapyDays of lifeChi-square testAggressive therapyBiologic therapyPatient characteristicsTreatment patternsThe adoption of immune checkpoint inhibitors and patterns of care at the end of life.
Riaz F, Gan G, Li F, Davidoff A, Adelson K, Presley C, Adamson B, Shaw P, Parikh R, Mamtani R, Gross C. The adoption of immune checkpoint inhibitors and patterns of care at the end of life. Journal Of Clinical Oncology 2020, 38: 12027-12027. DOI: 10.1200/jco.2020.38.15_suppl.12027.Peer-Reviewed Original ResearchNon-small cell lung cancerImmune checkpoint inhibitorsUse of chemotherapyMSS colon cancerEnd of lifeSystemic therapySystemic cancer therapyColon cancerFDA approvalCheckpoint inhibitorsBiologic therapyPatient characteristicsUse of ICIsCell lung cancerPatterns of careCare of patientsMicrosatellite stable colon cancerPearson's chi-square testPatient-level dataCancer therapyDays of lifeDe-identified databaseSignificant increaseChi-square testAggressive therapyEffects of a Communication Intervention Randomized Controlled Trial to Enable Goals-of-Care Discussions.
Bickell NA, Back AL, Adelson K, Gonsky JP, Egorova N, Pintova S, Lin JJ, Kozuch P, Bagiella E, Smith CB. Effects of a Communication Intervention Randomized Controlled Trial to Enable Goals-of-Care Discussions. JCO Oncology Practice 2020, 16: e1015-e1028. PMID: 32374710, DOI: 10.1200/op.20.00040.Peer-Reviewed Original ResearchConceptsElicit patient valuesEnd of lifeAdvanced cancerPatient valuesAggressive careGOC discussionsCare discussionsIntensive care unit admissionHigh care utilizationCare unit admissionMean hospitalizationTraining oncologistsUnit admissionUC patientsAggressive treatmentCare utilizationBlock randomizationCommunication skills trainingOncologistsPatientsCancerCommunication interventionsPrevalenceLife expectancyLast month
2018
Simple interventions to decrease use of chemotherapy in patients at the end of life.
Chiang A, Adelson K, Kapo J, Severino K, Lilenbaum R. Simple interventions to decrease use of chemotherapy in patients at the end of life. Journal Of Clinical Oncology 2018, 36: 181-181. DOI: 10.1200/jco.2018.36.30_suppl.181.Peer-Reviewed Original ResearchDays of lifeCourse of illnessEnd of lifeDay of deathGOC conversationsPrimary oncologistCare centerEarly palliative care referralPalliative care referralUse of chemotherapyPalliative care trainingChemotherapy utilizationCare referralPoor prognosisGOC discussionsCancer patientsUnnecessary treatmentGeneral oncologistsCare conversationsPost interventionPatientsChemotherapyMultidisciplinary teamPatient carePhysicians' skills
2017
An EPIC electronic decision support tool to identify percentage of patients with stage IV thoracic or gastrointestinal malignancy who would benefit from concurrent palliative care but do not currently receive it.
Adelson K, Trant A, Framski K, Swidler M, Kashyap N. An EPIC electronic decision support tool to identify percentage of patients with stage IV thoracic or gastrointestinal malignancy who would benefit from concurrent palliative care but do not currently receive it. Journal Of Clinical Oncology 2017, 35: 133-133. DOI: 10.1200/jco.2017.35.8_suppl.133.Peer-Reviewed Original ResearchEpic electronic health recordConcurrent palliative carePalliative careOncologic careElectronic decision support toolPalliative care visitsPC referral rateSmilow Cancer HospitalStandard oncologic careYale-New HavenPalliative care consultStage IV diseasePercentage of patientsPalliative care servicesHealth care utilizationICD-10 diagnosisQuality of lifeVolume of patientsElectronic health recordsAlign careCare consultEligible patientsPC referralEnd of lifeIOM guidelines
2015
Chemotherapy Use, Performance Status, and Quality of Life at the End of Life
Prigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, Schneider BJ, Garrido MM, Reid MC, Berlin DA, Adelson KB, Neugut AI, Maciejewski PK. Chemotherapy Use, Performance Status, and Quality of Life at the End of Life. JAMA Oncology 2015, 1: 778-784. PMID: 26203912, PMCID: PMC4828728, DOI: 10.1001/jamaoncol.2015.2378.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsChi-Square DistributionFemaleHealth StatusHealth Status IndicatorsHumansLogistic ModelsLongitudinal StudiesMaleMiddle AgedMultivariate AnalysisNeoplasm MetastasisNeoplasm StagingNeoplasmsOdds RatioPalliative CarePatient SelectionProportional Hazards ModelsProspective StudiesQuality of LifeRisk AssessmentRisk FactorsStress, PsychologicalSurveys and QuestionnairesTerminal CareTime FactorsTreatment OutcomeUnited StatesConceptsEnd-stage cancerGood performance statusBaseline performance statusQuality of lifeChemotherapy usePatient performance statusPerformance statusPalliative chemotherapyEastern Cooperative Oncology Group performance statusGood baseline performance statusPoor baseline performance statusProgressive metastatic cancerProgressive metastatic diseasePoor performance statusSolid tumor patientsClinical Oncology guidelinesLongitudinal cohort studyOutpatient oncology clinicsChemotherapy regimenEnd of lifeCohort studyMetastatic diseaseOncology clinicPatient survivalOncology guidelines